fbpx

molecules of the month

IM156

oral protein-complex 1 (OXPHOS) inhibitor

200-800 mg QD, phase I, cancer/IPF

from metformin

J. Pharmacol. Exp. Ther.

ImmunoMet Therapeutics

Chemical structure of IM156
1 min read

The ImmunoMet OXPHOS modulator (PC1 inhibitor), IM156, is a derivative of the long-used biguanide diabetes drug, metformin, that appears to have activity in lung fibrosis models. The therapeutic hypothesis for IPF is that myofibroblasts play an essential role in extracellular matrix remodeling and fibrogenesis that lead to loss of pulmonary function. A complex process of metabolic reprogramming is critical to the myofibroblast phenotype and disruption of myofibroblast metabolic pathways may have anti-fibrotic effects. A phase I dose escalation study was completed in cancer patients and there are plans to conduct a Ph. II study in IPF.


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: